CPX - 351 和 midostaurin 联合治疗 FLT3 突变的继发性急性髓系白血病患者 : 三例并文献复习。
关键词: AML CPX-351 FLT3 inhibitors combination therapies novel therapies
Mesh : Aged Allografts Anemia, Refractory, with Excess of Blasts / physiopathology Aniline Compounds / administration & dosage Antineoplastic Combined Chemotherapy Protocols / therapeutic use Azacitidine / administration & dosage Breast Neoplasms / radiotherapy surgery Bridged Bicyclo Compounds, Heterocyclic / administration & dosage Clinical Trials, Phase III as Topic Cytarabine / administration & dosage Daunorubicin / administration & dosage Fatal Outcome Female Humans Leukemia, Myeloid, Acute / drug therapy etiology genetics pathology Liposomes Male Middle Aged Myelodysplastic Syndromes / physiopathology Neoplasm, Residual Neoplasms, Radiation-Induced / drug therapy genetics mortality pathology Oncogene Proteins, Fusion / antagonists & inhibitors genetics Peripheral Blood Stem Cell Transplantation Point Mutation Protein Kinase Inhibitors / administration & dosage Pyrazines / administration & dosage Remission Induction Salvage Therapy Staurosporine / administration & dosage analogs & derivatives Sulfonamides / administration & dosage fms-Like Tyrosine Kinase 3 / antagonists & inhibitors genetics
来 源:
DOI:10.1111/bjh.16800
PDF(Sci-hub)